Dose Rate and Therapeutic Gain
There is a consensus that previous difficulties encountered in U.S. clinical trials of NCT resulted from the use of inorganic compounds showing no tumor selectivity, and the use of thermal neutron beams which are known to have poor penetration in tissue (HVL ≈ 1.8 cm). Consequently, normal surface tissues were over-exposed, while viable tumor remained at depth. Since then, these problems have been largely circumvented through the development of epithermal neutron beams with better tissue penetration, and the synthesis of various boronated biomolecules which demonstrate tumor selectivity.
KeywordsNeutron Beam Boron Neutron Capture Therapy Therapeutic Gain Effective Dose Rate Boron Hydride
Unable to display preview. Download preview PDF.
- 2.D. Gabel, S. Foster, and R. G. Fairchild, The Monte-Carlo simulation of the biological effect of the 10B(Nna)7Li reaction in cells and tissue and its implication for boron neutron capture therapy, Radiat. Res. 111: 14 (1987).Google Scholar
- 3.B. J. Hall, “Radiobiology for the Radiologist,” Harper and Rowe, New York (1986).Google Scholar
- 4.B. S. Hilaris, ed., “Handbook of Interstitial Brachytherapy”, Publishing Science Group Inc., Criton, MA (1975).Google Scholar
- 5.H. Hatanaka, ed., “Boron Neutron Capture Therapy for Tumors,” Nishimura Co., Ltd., Japan (1986).Google Scholar
- 7.R. G. Fairchild and V. P. Bood, Current status of neutron capture therapy: Enhancement of tumor dose viabeam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluation, Int. J. Radiat. Oncol. Biol. Phys. 11: 831 (1985).PubMedCrossRefGoogle Scholar